Hyperparathyroidism secondary
Not recruitingStudy on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End-Stage Kidney Disease on Hemodialysis
Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End-Stage Kidney Disease on Hemodialysis
- Disease:Hyperparathyroidism secondary
- Substances:Upacicalcet Sodium Hydrate
Poland- Participants:18–64 years · 65+ years
- Substances:Upacicalcet Sodium Hydrate
- Sponsor:Pathalys Pharma Inc.



